AstraZeneca

67.89
-0.12 (-0.18%)
At close: Apr 15, 2025, 3:59 PM
67.87
-0.02%
After-hours: Apr 15, 2025, 06:00 PM EDT
-0.18%
Bid 67.7
Market Cap 420.94B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) 2.25
PE Ratio (ttm) 30.17
Forward PE 14.74
Analyst Buy
Ask 68.99
Volume 4,137,161
Avg. Volume (20D) 6,156,913
Open 68.06
Previous Close 68.01
Day's Range 67.32 - 68.40
52-Week Range 61.24 - 87.68
Beta 0.25

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardi...

Sector Healthcare
IPO Date May 12, 1993
Employees 94,300
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 32.58% from the latest price.

Stock Forecasts

Next Earnings Release

AstraZeneca is scheduled to release its earnings on Apr 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+2%
AstraZeneca shares are trading higher after the co... Unlock content with Pro Subscription
5 months ago
-7.22%
AstraZeneca shares are trading lower following a report suggesting that the company's insurance fraud involved senior executives in China.